Alternatives to Lomustine If You Can't Fill Your Prescription

Lomustine (Gleostine) is an important chemotherapy drug for brain tumors and Hodgkin's lymphoma — but its high cost, limited pharmacy availability, and exclusion from Medicare coverage means some patients struggle to fill their prescription on time. If you're in that situation, it's critical that you speak with your oncologist immediately rather than simply delaying treatment. In some cases, alternative therapies may be appropriate.

Important: Never switch, delay, or stop chemotherapy without consulting your oncologist. The alternatives listed here are not interchangeable in all situations. Your oncologist must evaluate your specific tumor type, treatment history, and molecular profile before making any changes.

Why Lomustine May Be Hard to Replace

Lomustine is one of very few chemotherapy agents that effectively crosses the blood-brain barrier due to its high lipid solubility. This property makes it especially valuable for primary and metastatic brain tumors. It is also one of only a handful of FDA-approved chemotherapies for glioblastoma — the most common and aggressive malignant brain tumor. For certain patients, particularly those with MGMT promoter-methylated tumors, lomustine is the preferred or standard-of-care agent.

That said, your oncologist has several other agents to consider depending on the clinical situation. Here are the main alternatives discussed in clinical practice:

1. Temozolomide (Temodar)

Temozolomide is the most commonly used oral chemotherapy for glioblastoma and is standard first-line therapy (in combination with radiation) for newly diagnosed cases. Like lomustine, it is an alkylating agent, but it works by a different mechanism (methylating DNA) and is not a nitrosourea.

Temozolomide has a key advantage: it is generally covered by Medicare and most private insurance plans, and generic versions are widely available. It's taken daily for 5 out of every 28 days (in adjuvant settings) or daily during radiotherapy. However, it is most effective in patients with MGMT-methylated tumors and may not be the appropriate substitute for lomustine in all settings, especially at tumor recurrence.

2. Carmustine (BCNU / Gliadel Wafers)

Carmustine (brand name BiCNU for IV formulation; Gliadel for implantable wafers) is another nitrosourea in the same class as lomustine. It also crosses the blood-brain barrier and has a similar mechanism of action — alkylating DNA and RNA.

The key difference is route of administration: carmustine IV is given intravenously in a clinical setting, while Gliadel wafers are surgically implanted directly into the tumor cavity during brain surgery. These are not suitable home medications. Carmustine has cross-resistance with lomustine, meaning if lomustine has stopped working, carmustine may also be ineffective.

3. Bevacizumab (Avastin)

Bevacizumab (Avastin) is an anti-VEGF monoclonal antibody approved by the FDA for recurrent glioblastoma. It works by inhibiting angiogenesis — blocking the formation of new blood vessels that tumors need to grow. It's given intravenously every 2 weeks.

Bevacizumab has been studied in combination with lomustine for recurrent glioblastoma. While the combination improves progression-free survival compared to lomustine alone, it has not been shown to improve overall survival in randomized trials. Bevacizumab is generally covered by Medicare Part B as an intravenously administered drug, which is a significant access advantage over lomustine.

4. PCV Regimen (Procarbazine + Lomustine + Vincristine)

Lomustine is also a component of the PCV regimen — a combination of procarbazine, lomustine (CCNU), and vincristine — which is considered standard of care for certain lower-grade gliomas with IDH mutation. If lomustine is not available, replacing it within PCV is not straightforward and would require oncologist evaluation.

5. Regorafenib

Regorafenib (Stivarga) is a multi-kinase inhibitor that has shown promise in recurrent glioblastoma in phase II trials (the REGOMA study), demonstrating improved overall survival compared to lomustine in one study (7.4 months vs 5.9 months median OS). However, it is not yet a standard of care and would only be considered in select clinical situations or trials.

Alternatives for Hodgkin's Lymphoma

For patients taking lomustine as part of Hodgkin's lymphoma treatment (typically in relapsed or refractory settings), alternatives would depend on the specific regimen. Brentuximab vedotin, nivolumab, pembrolizumab, and DHAP/ICE salvage regimens may be options depending on prior treatment history. Your hematologist/oncologist will guide this decision.

The Bottom Line: Talk to Your Oncologist First

No alternative should be started without your oncologist's guidance. Before assuming lomustine is unavailable, use every resource available to locate it — including medfinder, which calls pharmacies near you to check availability. If lomustine truly cannot be sourced, your oncologist can evaluate whether an alternative is medically appropriate for your specific situation.

If cost is the reason you can't fill your lomustine prescription, read our guide on saving money on lomustine before giving up on obtaining it. Patient assistance programs, prescription discount cards, and savings programs may make lomustine accessible even without insurance coverage.